Diana Mercedes Hernández Corona

Dr. Diana Mercedes Hernández Corona

Centro Universitario de Tonalá, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
orcid
Jalisco

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Medicinal Food
Verified
Journal Article
Closed access
Diana Mercedes Hernández CoronaDiana Mercedes Hernández Corona
Diana Mercedes Hernández Corona
EMEsperanza Martínez-Abundis
Esperanza Martínez-Abundis
MGManuel González-Ortiz
Manuel González-Ortiz
The aim of this article is to evaluate the effect of fucoidan administration on insulin secretion and insulin sensitivity in overweight or obese adults. A randomized, double-blind, placebo-controlled clinical trial was carried out in 25 obese or overweight volunteers. Thirteen patients received an oral dose of 500 mg of fucoidan once daily before breakfast and 12 patients received placebo for 3 months. Before and after the intervention, fasting glucose and 2-h postload, total cholesterol, high-density lipoprotein cholesterol, triglycerides, and insulin levels were measured. Low-density lipoprotein cholesterol (LDL-C) and homeostasis model analysis formulas (HOMA) for β-cell function and insulin resistance were calculated. The results showed a significant decrease in diastolic blood pressure (71.7 ± 12.2 vs. 67.8 ± 13.8 mmHg; P<.05) and LDL-C (3.1 ± 0.5 vs. 2.7 ± 0.6 mmol/l; P<.01) with increase in insulin levels (60.6 ± 24.0 vs. 78.6 ± 32.4 pmol/l; P<.05), HOMA β-cell (35.0 ± 20.8 vs. 50.6 ± 18.7; P<.05) and HOMA IR (1.9 ± 1.2 vs. 2.6 ± 1.8; P<.05) were observed after fucoidan administration. We conclude that fucoidan administration during a 3-month period in overweight or obese adults decreased diastolic blood pressure and LDL-C concentrations, increasing insulin secretion and insulin resistance.

25 August 2020 in Global Public Health
Verified
Journal Article
Closed access
TGTonatiuh González-Heredia
Tonatiuh González-Heredia
LGLeivy Patricia González-Ramírez
Leivy Patricia González-Ramírez
Diana Mercedes Hernández CoronaDiana Mercedes Hernández Corona
Diana Mercedes Hernández Corona
EMEugenio Alejandro Maciel-Hernández
Eugenio Alejandro Maciel-Hernández
A relationship between anxious depression has been proposed in patients with diabetes, which may contribute to the lack of medication adherence. The aim of this study was to investigate if there is a relationship between depression and / or anxiety with medication adherence and glycemic control in patients with type 2 Diabetes Mellitus (DM2). An analytical, cross-sectional study was carried out in the internal medicine outpatient clinic of a Hospital in Mexico. Patients with DM2 participated over a period from November 2015 to January 2016. The Morisky scale for medication adherence, and the Goldberg anxiety and depression scale were conducted for each patient. Data was collected from a total of 179 patients. There was a significant difference between anxious depression and medication adherence (p < 0.001) using logistic regression with an R2 of 0.136. There was also a significant difference between anxiety and glycemic control (p < 0.001) with an R2 of 0.175, however no significant difference was found between glycemic control and anxious depression. Our findings demonstrate that patients who suffer from anxious depression also tend to have reduced medication adherence, and anxiety was associated with poor glycemic control in patients with DM2 within the Mexican population.

26 March 2020 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MCMariana Chávez-Tostado
Mariana Chávez-Tostado
GCGabino Cervantes-Guevara
Gabino Cervantes-Guevara
SLSandra Estefanía López-Alvarado
Sandra Estefanía López-Alvarado
GCGabino Cervantes-Pérez
Gabino Cervantes-Pérez
FCFrancisco José Barbosa Camacho
Francisco José Barbosa Camacho
AGAlejandro González-Ojeda
Alejandro González-Ojeda
Background: The prevalence of malnutrition remains high in hospitals but no “gold standard” has been established to identify nutritional risks adequately. The Nutrition Risk Screening-2002 (NRS-2002), Subjective Global Assessment (SGA), and Controlling Nutritional Status Index (CONUT) are widely used screening tools, but their efficacy has not yet been compared in Mexican patients. Here, we aimed to compare the efficacy of these tools in identifying nutritional risks within the first 48 h of admission in a group of patients with gastrointestinal diseases. Methods: This was a cross-sectional study of 196 patients. The results of the screening tools, length of hospital stay, serum albumin and cholesterol concentrations, lymphocyte counts, age, body mass index (BMI), complications, and mortality were analyzed. Kappa (κ) statistics were applied to determine the degree of agreement between tools. The performances of the screening tools in predicting complications and mortality were assessed using binary logistic regression. Results: The NRS-2002, SGA, and CONUT tools identified nutritional risk in 67, 74, and 51% of the patients, respectively. The observed agreements between tools were: NRS2002/SGA, κ = 0.53; CONUT/NRS-2002, κ = 0.42; and SGA/CONUT, κ = 0.36. Within age groups, the best agreement was found in those aged 51–65 years (κ = 0.68). CONUT and length of stay were both predictive for the number of complications. The number of complications and serum cholesterol concentrations were predictive for mortality. Conclusions: The proportion of patients identified as having nutritional risk was high using all three screening tools. SGA, NRS-2002, and CONUT had similar capacities for screening risk, but the best agreement was observed between NRS-2002 and SGA. Only CONUT predicted complications, but none of these tools performed well in predicting mortality.

27 November 2019 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
BCBetsabe Contreras-Haro
Betsabe Contreras-Haro
SHSandra Ofelia Hernandez-Gonzalez
Sandra Ofelia Hernandez-Gonzalez
LGLaura Gonzalez-Lopez
Laura Gonzalez-Lopez
MEMaria Claudia Espinel-Bermudez
Maria Claudia Espinel-Bermudez
LGLeonel Garcia-Benavides
Leonel Garcia-Benavides
JGJorge I. Gamez-Nava
Jorge I. Gamez-Nava
Background: Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequate sensitivity and specificity for IR, although this index has not yet been used in connective tissue disorders. The aim of this study was to evaluate the frequency of insulin resistance (IR) using the validated surrogate index of triglycerides and glucose (TyG index) and to explore factors associated with IR in Mexican women with RA or SLE. Methods: Ninety-five female RA and 57 SLE patients were included in a cross-sectional study. Clinical and epidemiological variables were evaluated. IR was assessed using the TyG index with a cutoff value of > 4.68. Logistic regression analysis was performed to identify factors associated with IR excluding confounders. Results: IR frequency in the entire sample was 50%, higher than the 10% observed in non-rheumatic controls (p < 0.001). The frequency of IR was similar in SLE (49.1%) and RA (50.5%, p = 0.8) patients. IR was associated with a longer duration of hypertension and higher total cholesterol and low density lipoprotein cholesterol levels. Based on multivariate analysis, the duration of hypertension (OR: 1.06; 95% CI 1.002–1.12, p = 0.04), waist circumference (OR: 1.04; 95% CI 1.01–1.08, p = 0.007), uric acid levels (OR: 1.46; 95% CI 1.08–1.97, p = 0.01), RA (OR: 4.87; 95% CI 1.31–18.78, p = 0.01) and SLE (OR: 4.22; 95% CI 1.06–16.74, p = 0.04) were the main risk factors for IR. Conclusions: This study shows that the TyG index is a useful screening test for IR in RA and SLE patients. Future longitudinal studies should be performed with the aim of identifying the predictive value of TyG index results for identifying complications linked to IR.

28 February 2017 in Acta Clinica Belgica
Verified
Journal Article
Closed access
MGManuel González-Ortiz
Manuel González-Ortiz
EMEsperanza Martínez-Abundis
Esperanza Martínez-Abundis
Diana Mercedes Hernández CoronaDiana Mercedes Hernández Corona
Diana Mercedes Hernández Corona
ARAlejandra M. Ramírez-Rodríguez
Alejandra M. Ramírez-Rodríguez
Aim: To evaluate the effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men without diabetes. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in obese male patients between 30 and 50years of age. Eighteen subjects were randomly assigned to two groups of nine patients each. During a 28-day period, subjects received 5mg orally of tadalafil or placebo each night. Patients were evaluated before and after the intervention. Total insulin secretion and first phase of insulin secretion were calculated by insulinogenic index and Stumvoll index, respectively, and insulin sensitivity was calculated using the Matsuda index. Tolerability and compliance were evaluated permanently throughout the study. Results: There were no significant differences after administration of tadalafil in total insulin secretion (0.820.45 vs. 0.61 +/- 0.27, p=0.594), first phase of insulin secretion (1332 +/- 487 vs. 1602 +/- 800, p=0.779) and insulin sensitivity (4.6 +/- 1.2 vs. 4.9 +/- 2.5, p=0.779). No significant differences were shown in other measurements. Conclusion: Tadalafil administration for 28days did not modify insulin secretion or insulin sensitivity in obese men.

1 August 2017 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
TGTonatiuh González-Heredia
Tonatiuh González-Heredia
Diana Mercedes Hernández CoronaDiana Mercedes Hernández Corona
Diana Mercedes Hernández Corona
MGManuel González-Ortiz
Manuel González-Ortiz
EAEsperanza Martinez Abundis
Esperanza Martinez Abundis
Background: Impaired glucose tolerance (IGT) and glycemic variability may be associated with increased risk of micro- and macrovascular complications. The aim of this study was to assess the effect of linagliptin versus metformin on glycemic variability in patients with IGT. Material and Methods: A randomized, double-blind clinical trial with parallel groups was carried out in 16 adult patients with IGT, overweight or obesity. All patients signed an informed consent. The therapies were randomly assigned: (a) metformin 500 mg bid (n = 8) or (b) linagliptin 5 mg a.m. and placebo p.m. (n = 8), both for 90 days. At the beginning of the trial and 3 months later, fasting glucose, glycated hemoglobin A1c, oral glucose tolerance test (OGTT), and glycemic variability [area under the curve (AUC) of glucose, mean amplitude of glycemic excursion (MAGE), standard deviation (SD) of glucose, coefficient of variation (CV) of glucose, and mean blood glucose (MBG)] were measured. Mann–Whitney U, Wilcoxon, and Fisher exact tests were used for statistical analyses. Results: Both groups were similar in basal characteristics. After linagliptin administration, a significant decrease in glucose levels at 120 min of OGTT (9.0 ± 0.9 vs. 6.9 ± 2.2 mmol/L, P = 0.012) was observed. Glycemic variability showed a similar behavior and there were no significant differences in the AUC, MAGE, SD of glucose, CV of glucose, and MBG between groups. Conclusion: Linagliptin administration resulted in better glycemic control according to the decrease of glucose levels by the OGTT at 120 min in patients with IGT. Meanwhile, glycemic variability was not modified in any of the study groups.